New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
about
Accelerating the development of a group A Streptococcus vaccine: an urgent public health needPrevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocolStrategies in the development of vaccines to prevent infections with group A streptococcusCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusMolecular and genomic characterization of pathogenic traits of group A Streptococcus pyogenesEpidemiology of Invasive Group A Streptococcal Disease in Alaska, 2001 to 2013.Streptococcal pharyngitis in schoolchildren in Bamako, Mali.Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.High Incidence of Invasive Group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, CanadaRegion specific and worldwide distribution of collagen-binding M proteins with PARF motifs among human pathogenic streptococcal isolates.Staphylococcal and streptococcal superantigen exotoxinsDisease manifestations and pathogenic mechanisms of Group A Streptococcus.StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice.Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece.Antimicrobial susceptibility patterns, emm type distribution and genetic diversity of Streptococcus pyogenes recovered in BrazilNon-invasive monitoring of Streptococcus pyogenes vaccine efficacy using biophotonic imagingEmergence of Streptococcus pyogenes emm102 causing toxic shock syndrome in Southern Taiwan during 2005-2012.Protective immunogenicity of group A streptococcal M-related proteins.Streptococcus pyogenes strains in Sao Paulo, Brazil: molecular characterization as a basis for StreptInCor coverage capacity analysisStreptococcus pyogenes emm Types and Clusters during a 7-Year Period (2007 to 2013) in Pharyngeal and Nonpharyngeal Pediatric Isolates.Clinical and microbiologic characteristics of invasive Streptococcus pyogenes infections in north and south India.Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New ZealandEpidemiology Analysis of Streptococcus pyogenes in a Hospital in Southern Taiwan by Use of the Updated emm Cluster Typing System.High Incidence of Invasive Group A Streptococcus Disease Caused by Strains of Uncommon emm Types in Thunder Bay, Ontario, Canada.Invasive Group A Streptococcus Infection among Children, Rural Kenya.Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children.Rationale and design of the African group A streptococcal infection registry: the AFROStrep studyDevelopment of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.Characteristics of group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011.Group A streptococcal strains isolated in Lao People's Democratic Republic from 2004 to 2013.Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease ModelsConserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding proteinImmunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverageCurrent insights in invasive group A streptococcal infections in pediatrics.Vaccination against rheumatic heart disease: a review of current research strategies and challenges.Preventing rheumatic fever: M-protein based vaccine.Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
P2860
Q26739210-62677F4D-984A-4EC6-82E5-6C42B4639925Q26796469-67B09133-2ACD-4F59-9571-65E5FABAAA80Q26863366-C348C58C-4E88-42A0-9D70-FAE45E18B1D2Q27009175-F8B50228-9001-4B42-A966-DBB5DC61F346Q28388496-0D6D4D83-8D27-41E5-BEA9-31C1DBC99ECEQ30202103-88EC8921-73C8-4FC0-A73A-2FF78B2CB803Q30301331-35B1E6AC-FB2E-438B-B63F-7376DBC786DCQ30427910-F3A64B76-6A44-4FC1-A60B-55D1808B6A5CQ33629144-251A6808-69EA-4569-8EE2-C4E95942B318Q34131103-195EBAFA-D3E7-4AF0-99A5-982CF1F7D476Q34355243-8580390B-C280-4348-ABFE-6DFA48887097Q34413457-C59B8F63-61AE-4BF2-A437-A4DD8E9DAB84Q34674395-E55EE5C7-6C03-4124-9620-D768BDEF4C50Q34971503-F9E0E6DD-BF65-4089-960C-8ED8A1F613D6Q34975899-B04BE746-E29B-4736-BAB6-151B7EA7FAABQ35054131-E0A28904-62A8-49CA-BB8C-5F53EF24DFE5Q35069734-198EEDD3-4BD4-4A29-A96E-D5655AC41A5FQ35122760-3F07ED75-3534-4EEF-9D42-D5A19392A575Q35737965-F21E6C11-0F97-415C-9133-5E47CFC8DB1CQ35757601-9B69F4F7-F1FF-4264-8A9C-8480AA71E9E6Q35942999-0E5A7DD7-9634-443C-9308-DBFDD41360EDQ36054412-F6076F29-6954-4E26-A391-7A9998EA5637Q36161774-5F4D66F7-714E-4A8B-951E-21E9215354B0Q36174083-737191C0-6675-47E5-81F6-D309A5BE3A6DQ36434400-3C474ECE-11BB-435C-90A8-6C87381AFEA7Q36434486-C935E93D-2C39-4C27-83A3-5E83B4CAF46CQ36525315-B465ABD0-80A4-4F8D-9570-5F742BAE2959Q36616151-93BCA8E2-7879-4651-B378-B9D51280332DQ36625203-371496ED-C59C-4E61-8282-A6B3B5D580D5Q36698378-B770CD44-A2A5-430D-8182-FA1999B1C714Q36752322-BEEF4869-670E-4FBA-B80B-32AEDB1F9D08Q36867527-C3B23247-651D-4482-930C-2BC9D6F987CDQ37027300-F542E368-5C66-4540-B437-577DBDF7759BQ37238510-8108CD60-00EE-485D-A63D-FAD7CAC2F10BQ37478261-75A907D6-30B6-4962-BBCE-ED363163215EQ37625963-FC646E72-F78F-4A88-92AE-FEF154174751Q37988376-5E0DE4E3-E57D-4E83-9113-44FC2E9AE76AQ38021366-37342AE3-31AE-44B2-AE11-598146D88DEAQ38192121-8E2E83DB-6956-4B21-9500-3ABC656A547BQ38612165-637AE087-8649-43F3-99F2-0AB8482DF42C
P2860
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
New 30-valent M protein-based ...... otypes of group A streptococci
@ast
New 30-valent M protein-based ...... otypes of group A streptococci
@en
type
label
New 30-valent M protein-based ...... otypes of group A streptococci
@ast
New 30-valent M protein-based ...... otypes of group A streptococci
@en
prefLabel
New 30-valent M protein-based ...... otypes of group A streptococci
@ast
New 30-valent M protein-based ...... otypes of group A streptococci
@en
P2093
P2860
P1433
P1476
New 30-valent M protein-based ...... otypes of group A streptococci
@en
P2093
Edna Y Chiang
James B Dale
Thomas A Penfound
William J Walton
P2860
P304
P356
10.1016/J.VACCINE.2011.09.005
P407
P577
2011-09-13T00:00:00Z